Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ: ABVC )

0.5390 +0.0154 (+2.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ABVC BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Nasdaq Down Over 100 Points; Crude Oil Rises 1%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite shedding more than 100 points on Thursday. 
Via Benzinga
What's happening With ABVC BioPharma Shares?
Via Benzinga
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
SEC Goes After 'MrZackMorris, 'Stock Sniper' For Alleged Fraud
Eight people connected to Atlas Trading, a Discord-based community, have been named in a complaint filed by the Securities and Exchange Commission (SEC). Co-founders of the forum, podcasters, and... 
Via Benzinga
ABVC BioPharma Provides Vitargus Update - Phase II Vitargus Study Protocol Received Thai FDA Approval
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Upgrades 
Via Benzinga
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Announces Vitargus Phase II Study Plan Approved by HREC in Australia
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. 
Via Benzinga
ABVC Biopharma Announces Letter to Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Selects Additional Vitargus Phase II Study Site
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million. 
Via Benzinga
Why Nikola Dropped Over 9%; Here Are 66 Biggest Movers From Yesterday
Gainers Mobile Global Esports Inc. (NASDAQ: MGAM) shares surged 103.9% to settle at $5.30 on Tuesday. Shares are in low-float territory; the issue has about 15 million shares in its float. 
Via Benzinga
ABVC Provides Oncology Pipeline Updates
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Provides Vitargus Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday, 52 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 63 companies set new 52-week lows. 
Via Benzinga
ABVC BioPharma Provides Vitargus Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
ABVC Biopharma Provides Enrolment Update In Mid-Stage Attention Deficit Disorder Study
ABVC Biopharma (NASDAQ: ABVC) provided an update on the enrollment progress in the Phase II Part II clinical study of its ADHD candidate (ABV-1505). 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.